Portola Pharmaceuticals - PTLA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.03
+0 (0.00%)
Get New Portola Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTLA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Portola Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.03.

This chart shows the closing price for PTLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Portola Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2020Morgan StanleyBoost TargetEqual Weight$14.00 ➝ $18.00Low
5/5/2020William BlairDowngradeHoldLow
5/5/2020CitigroupDowngradeBuy ➝ NeutralLow
4/23/2020Royal Bank of CanadaInitiated CoverageOutperform$20.00High
1/10/2020OppenheimerDowngradeOutperform ➝ Market Perform$40.00 ➝ $17.00High
1/10/2020CowenLower TargetOutperform$45.00 ➝ $35.00High
11/8/2019The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
11/5/2019CowenReiterated RatingBuy$45.00High
10/9/2019CitigroupLower TargetBuy$51.00 ➝ $44.00Medium
9/5/2019Morgan StanleyInitiated CoverageHold$37.00High
8/9/2019Morgan StanleySet TargetHold$37.00Medium
8/9/2019William BlairReiterated RatingBuyLow
8/8/2019CowenReiterated RatingBuy$45.00High
8/5/2019Credit Suisse GroupReiterated RatingNeutral ➝ Neutral$35.00High
7/10/2019Credit Suisse GroupReiterated RatingNeutralLow
6/17/2019William BlairReiterated RatingOutperformHigh
5/8/2019CowenReiterated RatingBuyHigh
4/12/2019OppenheimerSet TargetBuy$42.00Low
3/4/2019BNP ParibasBoost TargetOutperform ➝ Positive$30.00 ➝ $42.00High
2/8/2019OppenheimerSet TargetBuy$30.00Low
1/14/2019OppenheimerSet TargetBuy$30.00Medium
12/31/2018OppenheimerSet TargetBuy$30.00High
12/12/2018William BlairReiterated RatingOutperformHigh
12/9/2018OppenheimerSet TargetBuy$30.00Low
11/8/2018Credit Suisse GroupLower TargetNeutral ➝ Hold$34.00 ➝ $30.00Medium
11/8/2018OppenheimerSet TargetBuy$60.00 ➝ $30.00N/A
10/11/2018Morgan StanleyLower TargetEqual Weight$34.00 ➝ $32.00High
9/20/2018OppenheimerSet TargetBuy$60.00Low
9/12/2018William BlairReiterated RatingBuyMedium
9/10/2018OppenheimerSet TargetBuy$60.00Medium
8/27/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$28.00 ➝ $34.00High
8/27/2018William BlairReiterated RatingBuyHigh
8/26/2018OppenheimerSet TargetBuy$60.00High
8/13/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$45.00 ➝ $34.00High
8/10/2018CitigroupLower TargetBuy ➝ Buy$64.00 ➝ $50.00N/A
8/10/2018Credit Suisse GroupReiterated RatingNeutral ➝ Underperform$49.00 ➝ $28.00High
8/9/2018OppenheimerSet TargetBuy$80.00 ➝ $70.00High
8/9/2018CowenReiterated RatingBuyHigh
6/5/2018OppenheimerSet TargetBuy$80.00High
5/17/2018OppenheimerSet TargetBuy$80.00Low
5/7/2018Morgan StanleyReiterated RatingPositive ➝ Equal Weight$31.00 ➝ $46.00High
5/7/2018CitigroupBoost TargetBuy$64.00High
5/6/2018OppenheimerSet TargetBuy$67.00 ➝ $80.00High
3/21/2018OppenheimerReiterated RatingBuyLow
3/13/2018OppenheimerSet TargetBuy$67.00Low
3/13/2018William BlairReiterated RatingBuyMedium
3/13/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$53.00 ➝ $49.00High
3/1/2018William BlairReiterated RatingBuyHigh
3/1/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$65.00High
3/1/2018OppenheimerSet TargetBuy$72.00 ➝ $67.00High
2/22/2018Morgan StanleyLower TargetOverweight ➝ Overweight$74.00 ➝ $65.00Low
2/21/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$68.00 ➝ $53.00High
2/20/2018OppenheimerSet TargetBuy$72.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Portola Pharmaceuticals logo
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $18.03
Low: $18.03
High: $18.03

50 Day Range

MA: $18.03
Low: $18.03
High: $18.03

52 Week Range

Now: $18.03
Low: $5.31
High: $31.73

Volume

N/A

Average Volume

3,172,176 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Portola Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Portola Pharmaceuticals in the last twelve months:
View the latest analyst ratings for PTLA.

What is the current price target for Portola Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Portola Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Portola Pharmaceuticals in the next year.
View the latest price targets for PTLA.

What is the current consensus analyst rating for Portola Pharmaceuticals?

Portola Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PTLA.

What other companies compete with Portola Pharmaceuticals?

How do I contact Portola Pharmaceuticals' investor relations team?

Portola Pharmaceuticals' physical mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is 650-246-7000 and its investor relations email address is [email protected] The official website for Portola Pharmaceuticals is www.portola.com. Learn More about contacing Portola Pharmaceuticals investor relations.